109 related articles for article (PubMed ID: 20497633)
1. Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB/WF1 mice.
Lee SW; Kim BS
Clin Exp Rheumatol; 2010; 28(3):393-6. PubMed ID: 20497633
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of nephritis in lupus-prone mice by thalidomide.
Lee SW; Park YB; Yang J; Park KH; Lee SK; Choi KH; Kim BS
Rheumatology (Oxford); 2012 Dec; 51(12):2131-40. PubMed ID: 22923758
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.
Zoja C; Benigni A; Noris M; Corna D; Casiraghi F; Pagnoncelli M; Rottoli D; Abbate M; Remuzzi G
Kidney Int; 2001 Aug; 60(2):653-63. PubMed ID: 11473648
[TBL] [Abstract][Full Text] [Related]
4. Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW)F1 mice.
Lee SW; Park KH; Park S; Kim JH; Hong SY; Lee SK; Choi D; Park YB
Arthritis Rheum; 2013 Jul; 65(7):1902-12. PubMed ID: 23553192
[TBL] [Abstract][Full Text] [Related]
5. Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid.
Yung S; Zhang Q; Zhang CZ; Chan KW; Lui SL; Chan TM
Arthritis Rheum; 2009 Jul; 60(7):2071-82. PubMed ID: 19565476
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model.
Cheng CC; Lee YF; Lan JL; Wu MJ; Hsieh TY; Lin NN; Wang JM; Chiu YT
Lupus; 2013 May; 22(6):554-61. PubMed ID: 23478030
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
Hainz N; Thomas S; Neubert K; Meister S; Benz K; Rauh M; Daniel C; Wiesener M; Voll RE; Amann K
Nephron Exp Nephrol; 2012; 120(2):e47-58. PubMed ID: 22286140
[TBL] [Abstract][Full Text] [Related]
8. Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice.
Yung S; Zhang Q; Chau MK; Chan TM
Autoimmunity; 2015; 48(7):471-87. PubMed ID: 26099989
[TBL] [Abstract][Full Text] [Related]
9. Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil.
Yap DY; Yung S; Ma MK; Mok MM; Kwan LP; Chan GC; Chan TM
Lupus; 2014 Jun; 23(7):678-83. PubMed ID: 24554708
[TBL] [Abstract][Full Text] [Related]
10. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
Lui SL; Tsang R; Wong D; Chan KW; Chan TM; Fung PC; Lai KN
Lupus; 2002; 11(7):411-8. PubMed ID: 12195781
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice.
Yu CC; Yang CW; Wu MS; Ko YC; Huang CT; Hong JJ; Huang CC
J Lab Clin Med; 2001 Jul; 138(1):69-77. PubMed ID: 11433230
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease.
Corna D; Morigi M; Facchinetti D; Bertani T; Zoja C; Remuzzi G
Kidney Int; 1997 May; 51(5):1583-9. PubMed ID: 9150476
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib treatment prevents glomerulosclerosis associated with lupus nephritis in a murine model through suppressive effects on the immune and renin-angiotensin systems.
Matsuki-Muramoto Y; Nozawa K; Uomori K; Sekigawa I; Takasaki Y
Mod Rheumatol; 2017 Jan; 27(1):77-86. PubMed ID: 27166507
[TBL] [Abstract][Full Text] [Related]
14. Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice.
Ramos MA; Piñera C; Setién MA; Buelta L; de Cos MA; de Francisco AL; Merino R; Arias M
Nephrol Dial Transplant; 2003 May; 18(5):878-83. PubMed ID: 12686658
[TBL] [Abstract][Full Text] [Related]
15. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice.
Nozaki Y; Yamagata T; Yoo BS; Sugiyama M; Ikoma S; Kinoshita K; Funauchi M; Kanamaru A
Clin Exp Immunol; 2005 Jan; 139(1):74-83. PubMed ID: 15606616
[TBL] [Abstract][Full Text] [Related]
16. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.
F L; Y T; X P; L W; H W; Z S; H Z; Z H;
Lupus; 2008 Jul; 17(7):622-9. PubMed ID: 18625634
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
19. Lupus nephritis: treatment with mycophenolate mofetil.
Kapitsinou PP; Boletis JN; Skopouli FN; Boki KA; Moutsopoulos HM
Rheumatology (Oxford); 2004 Mar; 43(3):377-80. PubMed ID: 14963204
[TBL] [Abstract][Full Text] [Related]
20. New immunosuppresor strategies in the treatment of murine lupus nephritis.
Alperovich G; Rama I; Lloberas N; Franquesa M; Poveda R; Gomà M; Herrero-Fresneda I; Cruzado JM; Bolaños N; Carrera M; Grinyó JM; Torras J
Lupus; 2007; 16(1):18-24. PubMed ID: 17283580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
